FDA approves cryopreserved formulation of ReNeuron’s retinal stem cell therapy candidate
Notification of Preliminary Results
ReNeuron progresses clinical and regulatory strategy for the US with stroke programme based on positive FDA regulatory feedback
ReNeuron presents positive pre-clinical data with its ExoPr0 exosome therapy candidate at major scientific conference
ReNeuron awarded major UK cell therapy manufacturing grant
at 2017-06-23 16:17:14
15 minute delayed share price from London Stock Exchange provided by Euroland.
